Company intelligence / Profile preview

Monod Bio

Seattle, Washington, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Commercial

Overview

Monod Bio has demonstrated the ability to design custom de novo protein biosensors that emit a bioluminescent signal upon target recognition. These have been validated in detecting viral antigens, cancer markers, and cardiac biomarkers with results published in high-impact journals such as Nature and Nature Biotechnology. The company’s technology enables rapid, sensitive diagnostics but does not yet appear to have commercialized or entered clinical trials as of May 2025[4][3].

Therapeutic areas: OncologyCardiovascularInfectious Diseases
Modalities: De novo engineered proteins (biosensors)Protein-based diagnostics
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

LuxSit Pro

Commercial

Indications: Research tool, Diagnostics

Beyond the preview

Go deeper on Monod Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monod Bio.

Explore the full profile